By the grace of Allah, the two-day National Consultative Strategic Planning Workshop on the Regulatory Strategic Plan 2026–2030 concluded with comprehensive input from stakeholders across Pakistan’s national regulatory system.
Senior leadership guided the discussions, including Mr. Hamed Yaqoob Sheikh, Federal Secretary Ministry of NHSR&C, Dr. Obaidullah, CEO of DRAP, Ms. Ellen Thom, Deputy WHO Representative, and Prof. Dr. Ayesha Majeed Isani, Director General (Health). Their participation reinforced the workshop’s focus on aligning national priorities with public health objectives.
Public health and governance perspectives were strengthened by contributions from Prof. Dr. Shahzad Ali Khan, Vice Chancellor HSA, and Mr. Ayaz Kiani, Senior Consultant Public Health, while national technical experts provided the strategic framing that guided candid dialogue on achievements, gaps and future priorities for regulatory strengthening.
Representatives from DRAP, Provincial Drug Control Authorities, CDCs, Secretary PQCBs, academic institutions, QMS focal points and leading industry associations including PPMA, Pharma Bureau, HDAP, HCPA, PNMA and PEMDA, together with development partners WHO, UNDP, SIFC and RCCI, played a central role in shaping a unified national vision for the Regulatory Strategy.
All stakeholder inputs were comprehensively captured and will now be consolidated into the National Strategic Plan 2026–30. The workshop produced a cohesive set of priorities aimed at building a more resilient, trusted and globally aligned regulatory system for Pakistan.
The smooth execution of the consultation reflected close coordination within DRAP and partner institutions, supported by a core organizing team comprising Mr. Ajmal Sohail Asif, Mr. Mehmood Anwar (WHO), Mr. Asadullah (WHO), Dr. Hasan Afzaal, Dr. Haseeb Tariq, Mr. Ayub Naveed, Mr. Ammar Ashraf Awan and Mr. Abdul Mughees. Their efforts ensured focused sessions and clear next steps for implementing the Regulatory Strategy.
With shared insights and consensus on priorities, stakeholders have set the groundwork for advancing regulatory reform and improving access to safe, quality medicines under the National Strategic Plan 2026–30.
